ADAG Stock Analysis: Buy, Sell, or Hold?
ADAG - Adagene Inc. American Depositary Shares
$3.94
0.41 (11.61%)
▲
5d:
+10.06%
30d:
+15.88%
90d:
+6.78%
BUY
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Apr 01, 2026
0d
Get Alerted When ADAG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ADAG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ADAG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ADAG is currently trading at $3.94, which is considered extended relative to its 30-day fair value range of $3.40 to $3.81.
Technical Outlook: Technically, ADAG is in a uptrend. The price is approaching resistance at $4.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: ADAG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.40 (+138.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADAG is in a uptrend. The price is approaching resistance at $4.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: ADAG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.40 (+138.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.40 -
$3.81
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.6%)
- BULLISH: Trading 138.6% below Wall St target ($9.40)
Trading Range Analysis
30-Day Trading Range
$3.40 -
$3.81
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.16
Resistance Level
$4.02
Current Trend
Uptrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.58
Wall Street Target
$9.40
(+138.6%)
Revenue Growth (YoY)
7332.8%
Profit Margin
-229.6%
Share & Embed Analysis
Last updated: June 19, 2026 12:45 PM ET
Data refreshes hourly during market hours. Next update: 1:45 PM
Data refreshes hourly during market hours. Next update: 1:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADAG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 65 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 66 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 59 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 62 BUY |
